ArticleJournal of inflammation research2026
Value of the Platelet-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Product in the Evaluation of Systemic Lupus Erythematosus Disease Activity.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the value of the platelet-to-lymphocyte ratio (PLR) and platelet-to-lymphocyte product (PLP) in assessing systemic lupus erythematosus (SLE) disease activity. Methods: This retrospective, single-center study extracted clinical data from the electronic medical records of 418 participants. Disease activity was assessed using Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2000) and SLE Disease Activity Score (SLE-DAS). Results: In the overall cohort, PLR showed no correlation with SLEDAI 2000 (ρ = 0.041, P = 0.409) or SLE-DAS (ρ = -0.020, P = 0.693). However, among patients with normal platelet counts, PLR positively correlated with SLEDAI 2000 (ρ = 0.169, P = 0.003) and SLE-DAS (ρ = 0.238, P < 0.001), whereas no such association was observed in those with thrombocytopenia. Conversely, PLP showed a significant negative correlation with SLEDAI 2000 (ρ = -0.278, P < 0.001) and SLE-DAS (ρ = -0.378, P < 0.001), and these associations persisted regardless of platelet counts. Multiple linear regression showed that PLP was independently associated with SLEDAI 2000 (B = -0.004, P = 0.049) and SLE-DAS (B = -0.010, P = 0.005). Moreover, PLP was independently associated with glucocorticoid dose grading (ρ = -0.285, P < 0.001). For identifying moderate-to-severe disease activity (SLE-DAS score >7.64), PLP showed an area under the curve (AUC) of 0.698 (95% confidence interval [CI]: 0.642 to 0.754), with 82.3% sensitivity and 55.0% specificity, outperforming platelet (AUC = 0.638, 95% CI: 0.581 to 0.694) and lymphocyte (AUC = 0.652, 95% CI: 0.592 to 0.712) counts. Conclusion: PLP is a newly proposed biomarker that may assist with the clinical assessment of SLE disease activity. Due to the cross-sectional design, the findings should not guide treatment decisions. PLR is only associated with disease activity in patients with normal platelet counts and shows no association in those with thrombocytopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.